Research Topics
| Brian ConwaySummaryAffiliation: University of British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infectionJason Grebely
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Canada
Int J Drug Policy 18:437-43. 2007..Moreover, the treatment of HCV in current and former IDUs within a multidisciplinary DOT program can be successfully undertaken, resulting in ETRs similar to those reported in randomized controlled trials...- Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdineB Conway
Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z 1Y8, Canada
Clin Infect Dis 30:S130-4. 2000.... - Directly observed therapy for the management of HIV-infected patients in a methadone programBrian Conway
Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z2C7, Canada
Clin Infect Dis 38:S402-8. 2004..Treatment-limiting hepatic toxicity was rare. A DOT program of coadministered methadone and HAART can be implemented with good results, even for patients who continue to use cocaine... - The role of adherence to antiretroviral therapy in the management of HIV infectionBrian Conway
Department of Pharmacology and Therapeutics, University of British Columbia, Faculty of Medicine, Vancouver, British Columbia, Canada
J Acquir Immune Defic Syndr 45:S14-8. 2007.... - A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspectiveBrian Conway
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Clin Infect Dis 41:S73-8. 2005..Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind... - Pharmacology and clinical experience with amprenavirB Conway
University of British Columbia, Viridae Clinical Sciences, 1134 Burrard Street, Vancouver BC, V6Z 1Y8, Canada
Expert Opin Investig Drugs 9:371-82. 2000..Its specific role in therapy can only be clarified once the results of ongoing trials (particularly comparative trials of its use in previously treated patients) are available... - Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy programHarout K Tossonian
Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
J Acquir Immune Defic Syndr 45:324-7. 2007.... 
Primary drug resistance in antiretroviral-naïve injection drug usersHarout K Tossonian
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada
Int J Infect Dis 13:577-83. 2009..We evaluated the prevalence of primary HIV drug resistance in a population of 128 injection drug users (48 female) prior to initiating antiretroviral therapy...
Factors associated with spontaneous clearance of hepatitis C virus among illicit drug usersJason Grebely
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
Can J Gastroenterol 21:447-51. 2007..Spontaneous clearance of hepatitis C virus (HCV) occurs in approximately 25% of individuals...- Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug usersJason Grebely
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
J Gastroenterol Hepatol 22:1519-25. 2007.... - Current approaches to HCV infection in current and former injection drug usersJason Grebely
Vancouver Coastal Health, Vancouver, British Columbia, Canada
J Addict Dis 27:25-35. 2008..The development of such programs may be quite complex, but the ultimate benefit (for the treated population and for society as a whole) is certainly worth the effort... - The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy programJesse D Raffa
Department of Statistics, University of British Columbia, Vancouver, BC, Canada
Drug Alcohol Depend 89:306-9. 2007..We sought to evaluate the impact of ongoing illicit drug use on methadone adherence within a DOT program for the treatment of HIV-infection... - Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based TherapyHarout K Tossonian
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada
Open Virol J 1:8-13. 2007..033). Mutations at codon 135 do not affect response rates, but affect the pattern of development of NNRTI resistance mutations. This has important implications for the subsequent use of newer NNRTIs such as etravirine in salvage therapy... - Barriers associated with the treatment of hepatitis C virus infection among illicit drug usersJason Grebely
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
Drug Alcohol Depend 93:141-7. 2008..Illicit drug users account for the majority of cases of HCV infection in the developed world, but few have received treatment... - Conference report - antiretroviral therapy update from the 9th European AIDS ConferenceBrian Conway
Department of Pharmacology Therapeutics, University of British Columbia, Vancouver, British Columbia
MedGenMed 5:30. 2003 - Hepatitis C virus reinfection in injection drug usersJason Grebely
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
Hepatology 44:1139-45. 2006..23; 95% CI, 0.10-0.51, P < .001). In conclusion, individuals with clearance of HCV infection may have a lower risk of acquiring HCV than individuals who have never been infected, despite ongoing exposure to HCV... - Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?Brian Conway
Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, 201 1200 Burrard Street, Vancouver, BC, V6Z2C7, Canada
Curr Infect Dis Rep 13:68-74. 2011..As we redefine the potential benefits of cART on a broader scale, let us not sacrifice the gains that have been made until we are more certain of the potential benefits of the "seek and treat" strategy... - Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little
Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
N Engl J Med 347:385-94. 2002..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent... - Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA PanelMartin S Hirsch
Harvard Medical School, Boston, MA, USA
Clin Infect Dis 37:113-28. 2003..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation... - Drug resistance mutations in HIV-1Jonathan M Schapiro
Vanderbilt University Medical Center, Nashville, TN, USA
Top HIV Med 11:92-6. 2003 - CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapyMarina B Klein
Department of Medicine, Divisions of Infectious Diseases Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
Contemp Clin Trials 29:617-30. 2008..Effective prevention of a broad range of neuropsychiatric symptoms by citalopram has the potential to diminish PEG-IFN-alpha associated morbidity and consequently, allow a greater number of patients to complete full therapy... - Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutationsJesse D Raffa
J Acquir Immune Defic Syndr 47:397-9. 2008 - Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapyStephen D Shafran
University of Alberta, Edmonton, Alberta, Canada
Ann Intern Med 137:734-7. 2002..S. Public Health Service/Infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART... - A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164)Sharon L Walmsley
Department of Medicine, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
J Acquir Immune Defic Syndr 45:418-25. 2007..The primary endpoint was the percentage of patients with a 3-month sustained HIV RNA level <50 copies/mL... - Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenzFrank van Leth
Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Antivir Ther 9:721-8. 2004..To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL)... - And now for something completely simpleBrian Conway
Expert Rev Anti Infect Ther 2:1-4. 2004 - A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infectionFrederick M Hecht
University of California San Francisco, San Francisco, CA 94110, USA
J Infect Dis 194:725-33. 2006.... - Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents... - A phase II dose-escalating trial of clevudine in patients with chronic hepatitis BPatrick Marcellin
Service d Hepatologie, Hopital Beaujon, Clichy, France
Hepatology 40:140-8. 2004..The pharmacokinetic profile of clevudine was proportional to the dose. In conclusion, these results demonstrate the tolerability and potent activity of clevudine in HBV-infected patients and support further clinical study... - Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008.... - Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)Andrew R Zolopa
Stanford University School of Medicine, Stanford, CA 94305 5107, USA
Clin Infect Dis 41:92-9. 2005..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes... - Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodiesStephen D Shafran
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2B7
Clin Infect Dis 34:658-61. 2002..96%, and its overall accuracy was 99.96%. The Merlin POC test is highly accurate for the detection of HIV antibodies... - Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infectionBluma G Brenner
McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
J Virol 76:1753-61. 2002..These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence... - Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimenMona R Loutfy
Department of Medicine, University of Toronto, Toronto, Canada
HIV Clin Trials 8:259-68. 2007.... - Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch
Top HIV Med 11:150-4. 2003..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing... - Drug resistance mutations in HIV-1Victoria A Johnson
Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
Top HIV Med 11:215-21. 2003..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included... - Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown
University of Edinburgh, Edinburgh, Scotland
J Virol 78:2242-6. 2004..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection... - Update of the drug resistance mutations in HIV-1: Fall 2005Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 13:125-31. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility... - Morphologic changes in HIV-infected men: sorting fact from fictionMilan Khara
J Acquir Immune Defic Syndr 40:119-20. 2005 - Update of the Drug Resistance Mutations in HIV-1: 2005Victoria A Johnson
Veterans Affairs Medial Center, Birmingham, AL, USA
Top HIV Med 13:51-7. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility... - Monoclonal antibody hNM01 in HIV-infected patients: a phase I studyBruce J Dezube
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Clin Virol 31:S45-7. 2004..4 days). During hNMO1 therapy effects were observed on CD4 cell counts and plasma viral loads and further dose finding trials are necessary to better determine the therapeutic activity of hNM01 in HIV-infected individuals... - Update of the drug resistance mutations in HIV-1: 2004Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 12:119-24. 2004